This article discusses the relationship between homocysteine levels and cardiovascular disease (CVD), emphasizing the importance of evidence-based approaches in drug therapy. It outlines the STEPped Care framework—Safety, Tolerability, Effectiveness, and Price—to guide clinical decisions. The article highlights that hyperhomocysteinemia, a condition characterized by elevated homocysteine levels, is an independent risk factor for atherosclerosis and CVD. Homocysteine is a sulfur-containing amino acid derived from methionine, and its metabolism involves two pathways: remethylation (involving folate and vitamin B12) and transsulfuration (involving vitamin B6). Deficiencies in these nutrients can lead to hyperhomocysteinemia, which is associated with endothelial injury, free radical damage, and increased clotting factors. Numerous studies have shown a strong association between hyperhomocysteinemia and CVD, including coronary heart disease (CHD), peripheral vascular disease, stroke, and venous thrombosis. However, routine measurement of homocysteine levels is not common in clinical practice. Folic acid is the most effective agent for lowering homocysteine levels, with doses below 2 mg generally safe. The US Public Health Service recommends folic acid supplementation for women of childbearing potential to prevent neural tube defects. The FDA has mandated folic acid fortification in enriched grain products, which may help reduce CHD mortality. While folic acid is effective in lowering homocysteine levels, the optimal dose and its impact on CVD outcomes remain unclear. Several studies have shown that folic acid supplementation reduces homocysteine concentrations, but randomized controlled trials are needed to confirm its effectiveness in preventing CVD. The article also discusses the safety and tolerability of folic acid, noting that it is generally well-tolerated, though it may mask vitamin B12 deficiency in some cases. The cost of folic acid is low, making it an affordable option for reducing homocysteine levels. In conclusion, hyperhomocysteinemia is an independent risk factor for CVD, and folic acid is a promising intervention for lowering homocysteine levels. However, more research is needed to determine the optimal dose and its role in preventing CVD. Despite the lack of conclusive evidence, folic acid supplementation is recommended for individuals at risk of CVD, especially those with documented CHD or premature atherosclerosis.This article discusses the relationship between homocysteine levels and cardiovascular disease (CVD), emphasizing the importance of evidence-based approaches in drug therapy. It outlines the STEPped Care framework—Safety, Tolerability, Effectiveness, and Price—to guide clinical decisions. The article highlights that hyperhomocysteinemia, a condition characterized by elevated homocysteine levels, is an independent risk factor for atherosclerosis and CVD. Homocysteine is a sulfur-containing amino acid derived from methionine, and its metabolism involves two pathways: remethylation (involving folate and vitamin B12) and transsulfuration (involving vitamin B6). Deficiencies in these nutrients can lead to hyperhomocysteinemia, which is associated with endothelial injury, free radical damage, and increased clotting factors. Numerous studies have shown a strong association between hyperhomocysteinemia and CVD, including coronary heart disease (CHD), peripheral vascular disease, stroke, and venous thrombosis. However, routine measurement of homocysteine levels is not common in clinical practice. Folic acid is the most effective agent for lowering homocysteine levels, with doses below 2 mg generally safe. The US Public Health Service recommends folic acid supplementation for women of childbearing potential to prevent neural tube defects. The FDA has mandated folic acid fortification in enriched grain products, which may help reduce CHD mortality. While folic acid is effective in lowering homocysteine levels, the optimal dose and its impact on CVD outcomes remain unclear. Several studies have shown that folic acid supplementation reduces homocysteine concentrations, but randomized controlled trials are needed to confirm its effectiveness in preventing CVD. The article also discusses the safety and tolerability of folic acid, noting that it is generally well-tolerated, though it may mask vitamin B12 deficiency in some cases. The cost of folic acid is low, making it an affordable option for reducing homocysteine levels. In conclusion, hyperhomocysteinemia is an independent risk factor for CVD, and folic acid is a promising intervention for lowering homocysteine levels. However, more research is needed to determine the optimal dose and its role in preventing CVD. Despite the lack of conclusive evidence, folic acid supplementation is recommended for individuals at risk of CVD, especially those with documented CHD or premature atherosclerosis.